Abstract
Due to the unique sensory innervation of the teeth and face, orofacial pain can be challenging to diagnose and manage. Odontogenic pain, or ‘toothache', is the most common orofacial pain condition and encompasses the vast majority of pain which is presented to dental practitioners. While diagnosis is often straightforward, the clinical picture is occasionally unclear or contradictory, and in these situations, the clinician should be able to consider reasons other than the teeth for the patient's presenting complaint. The primary aim of managing odontogenic pain is to treat the underlying cause, often arising from the dental pulp or periapical tissues; however, several factors can make pre-, intra- and post-operative management of odontogenic pain challenging. This paper will consider key similarities and differences in the clinical presentation of odontogenic pain and other non-odontogenic causes of orofacial pain in order to help practitioners arrive at the correct diagnosis. We discuss evidence-based recommendations for intra- and post-operative management of acute odontogenic pain, and consider the underlying neurophysiological features which make orofacial pain challenging to manage.
Key points
-
Orofacial pain is unique and often difficult to diagnose due to mechanisms such as peripheral and central sensitisation, presenting a diagnostic challenge.
-
Other painful conditions (eg TMD) can increase the severity of, or even masquerade as, odontogenic pain.
-
Effective pain management may involve systemic approaches combined with local measures to enable effective treatment and reduce the risk of post-operative pain.
Similar content being viewed by others
Why is orofacial pain a special case?
Orofacial pain is universally reported as severe and debilitating; symptomatic irreversible pulpitis, the most common reason for presenting for urgent dental care, is, on average, rated as 8/10 in intensity, requiring almost universal use of pain-relieving medication and time away from work.1,2 Given that systemic antibiotics don't work for symptomatic irreversible pulpitis, operative intervention is mandatory,3 bringing challenges in diagnosis and intra- and post-operative pain control.
The orofacial structures have unique sensory innervation. Most parts of the body are innervated by neurons whose cell bodies reside in the dorsal root and which synapse with second order neurons in the spinal cord. Orofacial structures, however, are innervated by the trigeminal nerve, whose cell bodies reside within the trigeminal ganglion (TG), and which synapse with second order neurons in the trigeminal nuclei in the brainstem, before ascending to synapse further in higher brain structures (thalamus, cerebral cortex). These multiple synapses allow opportunities for incoming nociceptive signals to be modified (‘turned up'/‘turned down'). An additional trigeminal pathway has also been identified, bypassing trigeminal nuclei, and feeding nociceptive signals directly into circuits involved in emotion-, fear- and instinct-related brain centres (Fig. 1).4 This ‘direct route' offers fewer opportunities to modify nociceptive signals and may explain why orofacial pain is often more severe and emotive than pain elsewhere in the body.5,6,7
Innervation of the teeth. First-order neurons have cell bodies which reside in the trigeminal ganglion; their axons send signals from the tooth and go on to synapse with second-order neurons in the sub-nucleus caudalis of the trigeminal nuclear complex in the brainstem. Evidence from animal models suggest the presence of an additional route (dashed red line) in which primary trigeminal afferents synapse with second order neurons in the parabrachial nucleus, missing the brainstem, and offering a ‘direct' input to the brain4
Nociception and pain
Nociception is the process by which signals about real or potential damage to tissues in the periphery (parts of the body outside of the central nervous system) are sent to the brain. The main function of nociception is to allow the brain to produce the complex phenomenon we feel as pain. Pain often produces a behaviour designed to protect the individual from harm (eg withdrawing a hand from a fire); however, pain is not always the result of harm and is not always protective.8 In the orofacial region, nociceptive signals may arise from an inflamed dental pulp and ultimately go on to produce the painful experience of toothache. Patients with toothache may also experience sensitivity of surrounding unaffected areas, as well as radiation of their pain to distant areas. These features are caused by peripheral and central sensitisation.
Peripherally, classical inflammation produces numerous inflammatory mediators, such as histamine, bradykinin and prostaglandins, which cause sensitisation of nociceptors (pain-sensing nerve endings) within the pulp and periodontium and produce lowered stimulation thresholds and spontaneous firing of these neurons. Additionally, activated nociceptive neurons themselves release neuropeptides which cause similar sensitisation of nociceptors in a process called neurogenic inflammation.9,10,11,12 Finally, activated neurons sprout more terminal branches, thus widening the field from which they receive sensation,13 and pulpal nociceptors which are usually dormant become activated. The net result of these peripheral mechanisms is that pain experienced is disproportionate to the stimulus (hyperalgesia) and stimuli which would not normally be painful are perceived as such (allodynia). Depolarisation of neurons without any apparent stimulus also explains the phenomenon of spontaneous pain, commonly seen in toothache. As the pulp contains few mechanoreceptors, its proprioceptive capacity is poor,14 and it is not until the pathological process reaches the periodontal tissues, which are well-served by mechanoreceptors,15 that the pain usually becomes well localised.
As well as peripheral neurons, there is evidence that central sensitisation in response to nociceptive signals from the dentoalveolar structures may also occur.16 At the level of the TG, activation of satellite cells, release of pro-inflammatory mediators and upregulation of N-methyl-D-aspartate (NMDA) receptors leads to further sensitisation.17,18,19,20,21 Given that all the cell bodies for trigeminal sensory afferents reside in the TG, it is easy to understand why, within this neuro-inflammatory environment, adjacent neurons may be affected, resulting in referred pain and further driving the reduced threshold for neuronal activation. Similar mechanisms are seen within the brainstem in the trigeminal nucleus, with the upregulation of postsynaptic NMDA receptors and activation of microglia and astrocytes, resulting in further pro-inflammatory cytokine release.22 These changes further add to difficulty in diagnosis due to referred pain and a widened field of perceived pain.
These central mechanisms may also drive or influence neuropathic pain, where despite the removal of a stimulus, or resolution of peripheral pathology (eg post-traumatic trigeminal neuropathic pain, discussed below) painful symptoms remain.23 In this scenario, while the patient may complain of toothache from a seemingly healthy tooth, nociceptive signals arising from the pulp or periodontal tissues are not driving the patient's pain, but rather a problem higher up the pain pathway.24
Odontogenic pain: endodontic diagnosis
Pain of endodontic origin may currently be considered in the context of pulp and apical diagnoses, based on the American Association of Endodontists diagnostic criteria (Table 1).25,26 This system is simple to use and appropriate in most clinical situations, but is relatively inflexible, dividing pulpitis into dichotomous ‘reversible' or ‘irreversible' diagnoses. Any experienced dental practitioner will have managed cases which do not align perfectly with such criteria, hence the suggestion by Wolters et al. to introduce a more flexible system of ‘initial', ‘mild', ‘moderate' or ‘severe' pulpitis designed to align to increasing levels of intervention from simple caries management, through vital pulp treatments and finally root canal treatment.27
Whichever diagnostic system is favoured, extensive clinical evaluation is needed. This starts with a detailed pain history, followed by clinical examination aimed at identifying non-odontogenic causes of pain (eg TMD), the presence of swelling or a sinus, occlusal factors, periodontal diagnoses (eg narrow pocket suggesting root fracture, endodontic-periodontal lesions), pulp diagnosis (using sensibility tests or vitality tests) and apical diagnosis (through percussion testing and further investigations such as periapical radiography or cone-beam computed tomography [CBCT]). To test for pulp vitality, surrogate measures such as thermal testing and electronic pulp testing (EPT) have excellent sensitivity and specificity, especially when combined.28 In contrast, percussion testing has a lower sensitivity and specificity. True measures of pulp vitality, such as measures of blood flow (eg pulse oximetry), have up to 98% sensitivity and specificity but are not yet widely available.29,30
Unlike pulp diagnosis, the apical diagnosis is often more straightforward, with more localised pain and other signs such as a lack of response to sensibility tests, tenderness to percussion, and signs of bone destruction on a radiograph or CBCT.
Intra-operative management of odontogenic pain
Management of intra-operative pain to facilitate operative acute endodontic care is a priority for clinicians and patients. Positive intra-operative management has also been shown reduce the risk of persistent pain following endodontic treatment and so is critical for immediate management and longer-term outcomes.31 However, achieving anaesthesia is often more challenging for patients with acute dental pain.32,33 Peripherally increased levels of inflammatory mediators, phenotypic changes in ion channels, nociceptor activation and sensitisation, and nerve sprouting all account for increased neuronal activity even in the presence of local anaesthetic (LA) solutions. Furthermore, peripherally applied LA solutions would not be expected to attenuate central sensitisation which will continue to exaggerate nociceptive responses to peripheral stimuli.34 For those with swelling, distortion of anatomical landmarks, trismus and tissue acidity further complicate the process of anaesthesia. Overcoming anaesthetic difficulties can be considered in terms of anaesthetic agents, supplementary techniques and systemic approaches (Box 1).
Anaesthetic agent
In addition to simply increasing volume,35 administering 4% articaine with 1:100,000 adrenaline for inferior alveolar nerve block (IANB) and buccal infiltration has been shown to be more effective than using 2% lidocaine with 1:80,000 adrenaline,36,37 especially in cases of symptomatic irreversible pulpitis.38 The use of 4% articaine for inferior alveolar nerve block (IDB) has been a contentious issue over the last couple of decades, due to reported increased incidence of sensory disturbance compared to 2% lidocaine.39,40 However, recent high-quality evidence suggests there may be no increased risk of sensory disturbance using 4% articaine compared to 2% lidocaine, therefore given its therapeutic benefit, this approach is now worthy of consideration.41 Additionally, supplementary techniques such as intraosseous injections have been shown in large studies to have superior anaesthetic success rates to alternative techniques, and may therefore be useful in cases of difficult-to-achieve anaesthesia.42
Supplementary techniques
A range of supplementary techniques, outlined in Table 2, can be used to support anaesthetic success. These include supplemental infiltrations with 4% articaine,43 intraligamentary, intraosseous, or intra-pulpal injections, and high mandibular blocks.34
Systemic approaches
Some studies have highlighted the use of pre-operative systemic non-steroidal anti-inflammatory drugs (NSAIDS) or corticosteroids (individually or in combination) as being beneficial for intra-operative anaesthesia and post-operative pain control.44 In particular, evidence from systematic reviews suggests that NSAIDs such as ibuprofen taken pre-emptively before a procedure improve the success rate of LA in cases of symptomatic irreversible pulpitis,45,46 and have the additional benefit of reducing prostaglandin synthesis, thereby reducing the potential for post-operative inflammation and sensitisation. Although ibuprofen is the most widely used NSAID in dentistry in the UK, other NSAIDs have been associated with a greater effect, including indomethacin, meloxicam, diclofenac potassium and piroxicam, but may not have gained in popularity due to different adverse effect profiles.45 Further, at this present time, only ibuprofen and diclofenac sodium are listed on the dental practitioner's formulary; therefore, in clinical practice, individuals attending in pain could be advised, when safe to do so, to take 600 mg oral ibuprofen or 50 mg diclofenac sodium one hour before their appointment time to maximise efficacy of LA treatment.47 This could be particularly beneficial for individuals at increased risk of the development of persistent pain, to pre-emptively mitigate inflammatory processes. Evidence review could lead to the addition of further NSAIDs to the dental practitioner's formulary providing the opportunity of a wider breath of pain management options for dental clinicians in the future.
Pulpal treatment
Once effective anaesthesia is achieved, treatment options for symptomatic irreversible pulpitis may include partial or complete pulpotomy, or pulpectomy. Where resources allow, it is desirable to aim for a ‘definitive' pulpotomy using calcium silicate cements. This is discussed in detail in the European Society of Endodontology position statement on deep caries and the exposed pulp.45 It is worth noting that ‘definitive' pulpotomies have been shown to offer effective pain relief within a few days, emphasising their suitability for first line treatment in suitable cases.48
In cases where a vital pulp treatment (eg pulpotomy using calcium silicate cement) is not feasible, due to resource limitations or uncontrollable pulpal haemorrhage, it may be desirable to undertake a pulpectomy. However, Eren (2018) found a pulpotomy is as effective as a pulpectomy for the management of pain in symptomatic irreversible pulpitis.49 It is therefore advisable in the resource-limited urgent dental appointment, and/or where pulpectomy is challenging, that a pulpotomy is undertaken. Further uncertainty exists around the use of medicaments to manage pain. Two UK-based studies found that around two-thirds of practitioners currently place antibiotic/corticosteroid dressings into teeth following pulpotomy or pulpectomy.50,51 For pain relief in symptomatic irreversible pulpitis, there is no clear benefit of using such dressings above simple excision of irreversibly inflamed tissue and the placement of damp cotton wool or calcium hydroxide,52 suggesting the latter is appropriate, especially in the current climate of antimicrobial stewardship.53
In cases of acute or chronic abscess, although achieving anaesthesia can be challenging, drainage of infection through incision and/or extirpation and instrumentation to gain apical patency is usually effective.
Clinical experience
Our ability as clinicians to manage the patient experience can have a significant effect on pain management. Nixdorf et al. showed that patient treatment expectation being ‘very good' resulted in 61% decreased risk of persistent pain following root canal treatment.54 Environmental factors that clinician's control can also support positive pain management. For example, creating a relaxing environment with instrumental music has been shown to reduce intra- and post-operative pain and anxiety during surgical dental treatment.55
Post-operative pain management
Despite best efforts, a recent study undertaken in primary care suggests that one in four patients managed for symptomatic irreversible pulpitis may return due to pain within seven days.52 It is likely that the combined effect of peripheral and central sensitisation drives this finding. Positive post-operative pain management is important for every patient, but particularly so for those at increased risk of persistent pain conditions (Box 2).
Oral analgesics
Analgesic advice for patients with odontogenic pain should revolve mainly around NSAIDs such as ibuprofen. Given the role of prostaglandins in pulp inflammation and neuronal sensitisation outlined earlier, this class of drugs are the most effective option.56 Combining ibuprofen with paracetamol appears to offer enhanced analgesia over NSAIDs alone, with the effect being synergistic rather than merely additive,45,57 although a recent systematic review found this effect was not significant unless combined with caffeine.56 Other NSAID drugs have been studied, including Naproxen and Ketoprofen, which both reduced post-operative endodontic pain more than ibuprofen, although this was not significant.56 This perhaps highlights the need for further research in this area.
In contrast, centrally acting analgesics such as opioids (eg codeine) offer limited benefit in odontogenic pain, even when combined with NSAIDs.58 Given their adverse effect profile, they are best avoided. Optimising post-operative dosage (where appropriate, short courses of 600 mg oral ibuprofen TDS or QDS in preference of 400 mg doses) and improved patient advice (leaflets or patient-specific letters outlining analgesic advice) have been shown to significantly improve post-operative pain levels.59
In addition to the benefits of pre-operative administration of NSAIDs in enhancing LA effectiveness discussed earlier, there are further benefits of pre-operative administration for post-operative pain experience. Their use pre-operatively has been shown to be an important predictor for reduced post-operative pain following the endodontic management of symptomatic irreversible pulpitis.45 One under-used approach may be to administer oral corticosteroids pre-operatively, which has been shown to reduce post-operative pain scores by up to 30%.60
Operative procedures
Root canal treatment in the absence of infection, such as cases of symptomatic irreversible pulpitis, may be best managed in a single visit.61,62 Careful technique, such as minimising the extrusion of potentially infected dentine debris and thorough chemo-mechanical disinfection, may minimise the risk of flare-up, post-operative pain and post-treatment disease.63,64 The provision of a definitive restoration as soon as possible may also minimise the risk of reinfection and enhance tooth survival in the long run.65 Upon completion of an operative procedure, application of a long-acting LA (eg levobupivacaine) can be considered to enhance duration of post-operative pain control (Table 2).66
Non-odontogenic orofacial pain
While most commonly odontogenic in origin, orofacial pain may also be caused by a musculoskeletal, neuropathic (nerve-based), neurovascular (eg migraine) or idiopathic process. Clinicians should hold a high index of suspicion for signs and symptoms suggestive of pain of non-odontogenic origin, which can present either at the patient's primary or concurrent pain source (Box 3).
Temporomandibular disorders
Considering their prevalence, it is probably unsurprising that temporomandibular disorders (TMD) are frequently misdiagnosed as odontogenic pain. A recent study investigating patients diagnosed with odontogenic pain in an endodontic department found that 8% of cases had TMD as the sole aetiology (no odontogenic cause), and 20% had TMD as a major factor in a combined aetiology.67 TMD pain symptoms (dull, throbbing ache) may mimic odontogenic pain and pain in TMD may refer to molar (mandibular>maxillary) and premolar (maxillary>mandibular) teeth, leading to diagnostic difficulty.68 Endodontic treatment itself often exacerbates TMD symptoms due to prolonged mouth opening, and following endodontic treatment, prolonged pain form an odontogenic cause (treated or adjacent tooth) is equally prevalent to pain from TMD.69 Such findings highlight the importance of clinicians considering the following points:
-
Could TMD be the primary causative factor of the patient's complaint?
-
Could an individual's TMD be contributing to their current pain experience?
Fortunately, identification of TMD is relatively straightforward. Box 4 provides an examination summary to help clinicians identify TMD. For detailed diagnostic and management advice, referral to the recently published guideline Management of painful TMD in adults is advised.70
Post-traumatic trigeminal neuropathic pain
Persistent pain following endodontic treatment is a risk which can present regardless of the quality of the endodontic therapy. Post-traumatic trigeminal neuropathic pain (PTTN) is a rare condition following a preceding injury to trigeminal nerve fibres, which may include endodontic treatment, and can present in relation to a tooth with clinical and radiographic evidence of an otherwise satisfactory outcome (Box 5). Table 3 outlines key features and prevalence of PTTN. Early identification is important to avoid unnecessary interventive treatment, with an examination checklist suggested in Appendix 1. Though screening instruments show some potential, at present, there is no definitive diagnostic test. Combining symptomatic features and clinical examination findings can help to increase or decrease diagnostic suspicion.72 Any suspected case should be referred to a specialist care setting at the earliest point to optimise outcome.73
Percussion tests are not usually helpful in differentiating odontogenic pain and PTTN; however, tenderness to apical palpation suggests the presence of inflammatory dental disease (eg apical periodontitis).74,75 The presence of somatosensory change(s) are particularly helpful, including alterations in patients' perception of touch, pain, pressure and temperature. Both gain in sensation (eg hyperalgesia or allodynia) or reduction in sensation (eg hypoalgesia or paraesthesia) is observed compared to the unaffected side, and a difference is considered abnormal. Somatosensory abnormalities suggest a non-odontogenic cause such as PTTN and are rare in odontogenic pain or the absence of pain.76,77,78,79 Qualitative sensory testing (Box 6) allows chairside assessment of somatosensory change and does not require complex equipment.80
Risk factors for development of persistent orofacial pain
An awareness of population groups most at risk of persistent orofacial pain can help support diagnosis, inform the consent process and mitigate risk of development of persistent pain. The following features are associated with an increased risk of persistent orofacial pain (Box 7).
Duration and intensity of pain
Increased duration and intensity of odontogenic pain before endodontic treatment can adversely affect long-term outcome, with an increased risk of PTTN development.31,54 Nixdorf et al. demonstrated that for each additional day of pain experienced before endodontic treatment, there was a 19% increased risk of persistent pain.54 Swift, definitive management of odontogenic pain would therefore be expected to improve both short- and long-term patient outcomes.
Sex
Clinical studies demonstrate a four-fold increased risk of PTTN for women compared to men, while women have been shown to be marginally more affected by TMD than men.31,74,81 This phenomenon is not isolated to the orofacial region; persistent pain is more common in women and sex differences in pain reporting, perception, and endogenous pain modulation are accepted, though not yet fully understood.82
Comorbid pain
The experience of patients reporting worsening concomitant trigeminal pain issues, eg ‘my toothache has been so bad it has triggered my migraine', will have been experienced by many clinicians. In the context of comorbid pain, where induced changes in an individual's nociceptive system as a result of peripheral and central sensitization are pre-existing, the additive nociceptive burden effectively amplifies nociceptive messages, exacerbating the experience of each painful condition. One of the most common comorbidities which can exacerbate endodontic pain is TMD, as discussed previously.67 Following root canal treatment, those with a comorbid pain condition are 4.5 times more likely to develop persistent pain (PTTN).31
Other subtle features in an individual's history such as the presence of systemic or regional pain conditions (eg fibromyalgia), or a history of persistent pain/reports of ‘nerve damage' following surgery can suggest more generalised issues in an individual's pain processing, increasing the risk of persistent pain following treatment.
Psychosocial comorbidities
Depression and anxiety directly result in dysregulation of chemical messengers and neurotransmitters implicated in trigeminal pain.83,84,85,86 Indirectly, such conditions may be associated with reduction in self-care practices, healthcare avoidance, poor diet, and parafunctional habits. The resultant consequence is that those with psychosocial comorbidities such as stress, anxiety, depression, fear, or avoidance behaviours have been shown to display higher levels of pain intensity and pain related disability with respect to odontogenic and non-odontogenic pain conditions.87
Conclusion
While in many cases, managing odontogenic pain is straightforward, even the experienced clinician can be caught out by an unusual presentation. It is important that dental practitioners take time to consider alternative, non-odontogenic causes of pain where clinical features do not accord with a diagnosis of ‘toothache'. While management of an irreversibly inflamed pulp or apical abscess may be the primary goal of treatment, and the most important factor to alleviate the patient's pain, close attention to effective and individualised intra- and post-operative pain management may vastly improve the patient's experience of treatment and their clinical outcomes in the short- and long-term.
References
Edwards D, Rasaiah S, Hamzah Ahmed S et al. The financial and quality of life impact of urgent dental presentations: A cross-sectional study. Int Endod J 2023; 56: 697-709.
Currie C C, Stone S J, Durham J. Pain and problems: a prospective cross-sectional study of the impact of dental emergencies. J Oral Rehabil 2015; 42: 883-889.
Agnihotry A, Thompson W, Fedorowicz Z, van Zuuren E J, Sprakel J. Antibiotic use for irreversible pulpitis. Cochrane Database Syst Rev 2019; DOI: 10.1002/14651858.CD004969.pub5.
Rodriguez E, Sakurai K, Xu J et al. A craniofacial-specific monosynaptic circuit enables heightened affective pain. Nat Neurosci 2017; 20: 1734-1743.
Schmidt K, Forkmann K, Sinke C, Gratz M, Bitz A, Bingel U. The differential effect of trigeminal vs. peripheral pain stimulation on visual processing and memory encoding is influenced by pain-related fear. Neuroimage 2016; 134: 386-395.
Schmidt K, Schunke O, Forkmann K, Bingel U. Enhanced short-term sensitization of facial compared with limb heat pain. J Pain 2015; 16: 781-790.
Smith J G, Elias L A, Yilmaz Z et al. The psychosocial and affective burden of posttraumatic neuropathy following injuries to the trigeminal nerve. J Orofac Pain 2013; 27: 293-303.
Raja S N, Carr D B, Cohen M et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain 2020; 161: 1976-1982.
Bowles W R, Withrow J C, Lepinski A M, Hargreaves K M. Tissue levels of immunoreactive substance P are increased in patients with irreversible pulpitis. J Endod 2003; 29: 265-267.
Caviedes-Bucheli J, Camargo-Beltrán C, Gómez-la-Rotta A M, Moreno S C, Abello G C, González-Escobar J M. Expression of calcitonin gene-related peptide (CGRP) in irreversible acute pulpitis. J Endod 2004; 30: 201-204.
Park S H, Hsiao G Y, Huang G T. Role of substance P and calcitonin gene-related peptide in the regulation of interleukin-8 and monocyte chemotactic protein-1 expression in human dental pulp. Int Endod J 2004; 37: 185-192.
Killough S A, Lundy F T, Irwin C R. Substance P expression by human dental pulp fibroblasts: a potential role in neurogenic inflammation. J Endod 2009; 35: 73-77.
Kimberly C L, Byers M R. Inflammation of rat molar pulp and periodontium causes increased calcitonin gene-related peptide and axonal sprouting. Anat Rec 1988; 222: 289-300.
Närhi M, Bjørndal L, Pigg M, Fristad I, Haug R. Acute dental pain I. pulpal and dentinal pain. Nor Tannlegeforen Tid 2016; 126: 10-18.
Piancino M G, Isola G, Cannavale R et al. From periodontal mechanoreceptors to chewing motor control: A systematic review. Arch Oral Biol 2017; 78: 109-121.
Zhang S, Chiang C Y, Xie Y F et al. Central sensitization in thalamic nociceptive neurons induced by mustard oil application to rat molar tooth pulp. Neuroscience 2006; 142: 833-842.
Filippini H F, Scalzilli P A, Costa K M, Freitas R D S, Campos M M. Activation of trigeminal ganglion satellite glial cells in CFA-induced tooth pulp pain in rats. PLoS One 2018; DOI: 10.1371/journal.pone.0207411.
Watase T, Shimizu K, Komiya H, Ohara K, Iwata K, Ogiso B. Involvement of transient receptor potential vanilloid 1 channel expression in orofacial cutaneous hypersensitivity following tooth pulp inflammation. J Oral Sci 2018; 60: 8-13.
Komiya H, Shimizu K, Noma N et al. Role of Neuron-Glial Interaction Mediated by IL-1β in Ectopic Tooth Pain. J Dent Res 2018; 97: 467-475.
Lin J J, Du Y, Cai W K et al. Toll-like receptor 4 signaling in neurons of trigeminal ganglion contributes to nociception induced by acute pulpitis in rats. Sci Rep 2015; 5: 12549.
Lee C, Ramsey A, De Brito-Gariepy H et al. Molecular, cellular and behavioral changes associated with pathological pain signaling occur after dental pulp injury. Mol Pain 2017; DOI: 10.1177/1744806917715173.
Tsuboi Y, Iwata K, Dostrovsky J O, Chiang C Y, Sessle B J, Hu J W. Modulation of astroglial glutamine synthetase activity affects nociceptive behaviour and central sensitization of medullary dorsal horn nociceptive neurons in a rat model of chronic pulpitis. Eur J Neurosci 2011; 34: 292-302.
Cohen S P, Mao J. Neuropathic pain: mechanisms and their clinical implications. BMJ 2014; DOI: 10.1136/bmj.f7656.
Korczeniewska O A, Kohli D, Benoliel R, Baddireddy S M, Eliav E. Pathophysiology of Post-Traumatic Trigeminal Neuropathic Pain. Biomolecules 2022; 12: 1753.
American Association of Endodontists. Endodontic Diagnosis. 2013. Available at https://www.aae.org/specialty/wp-content/uploads/sites/2/2017/07/endodonticdiagnosisfall2013.pdf(accessed March 2025).
American Association of Endodontists. Glossary of Endodontic Terms. 2020. Available at https://www.aae.org/specialty/clinical-resources/glossary-endodontic-terms/ (accessed March 2025).
Wolters W J, Duncan H F, Tomson P L et al. Minimally invasive endodontics: a new diagnostic system for assessing pulpitis and subsequent treatment needs. Int Endod J 2017; 50: 825-829.
Pigg M, Nixdorf D R, Nguyen R H, Law A S. Validity of Preoperative Clinical Findings to Identify Dental Pulp Status: A National Dental Practice-Based Research Network Study. J Endod 2016; 42: 935-942.
Duncan H F, Kirkevang L L, Peters O A et al. Treatment of pulpal and apical disease: The European Society of Endodontology (ESE) S3-level clinical practice guideline. Int Endod J 2023; DOI: 10.1111/iej.13974.
Gopikrishna V, Tinagupta K, Kandaswamy D. Comparison of electrical, thermal, and pulse oximetry methods for assessing pulp vitality in recently traumatized teeth. J Endod 2007; 33: 531-535.
Polycarpou N, Ng Y L, Canavan D, Moles D R, Gulabivala K. Prevalence of persistent pain after endodontic treatment and factors affecting its occurrence in cases with complete radiographic healing. Int Endod J 2005; 38: 169-178.
Kayaoglu G, Gürel M, Saricam E, Ilhan M N, Ilk O. Predictive Model of Intraoperative Pain during Endodontic Treatment: Prospective Observational Clinical Study. J Endod 2016; 42: 36-41.
Segura-Egea J J, Cisneros-Cabello R, Llamas-Carreras J M, Velasco-Ortega E. Pain associated with root canal treatment. Int Endod J 2009; 42: 614-620.
Parirokh M, Abbott P V. Present status and future directions-Mechanisms and management of local anaesthetic failures. Int Endod J 2022; DOI: 10.1111/iej.13697.
Aggarwal V, Singla M, Miglani S, Kohli S, Singh S. Comparative evaluation of 1.8 mL and 3.6 mL of 2% lidocaine with 1:200:000 epinephrine for inferior alveolar nerve block in patients with irreversible pulpitis: a prospective, randomized single-blind study. J Endod 2012; 38: 753-756.
Khan Q, Noor N, Anayat N, Khan T S, Ahmed M. Comparison Of Anaesthetic Efficacy Of Articaine And Lidocaine In Nonsurgical Endodontic Treatment Of Permanent Mandibular Molars With Symptomatic Irreversible Pulpitis. A Randomized Clinical Trial. J Ayub Med Coll Abbottabad 2021; 33: 192-197.
Nagendrababu V, Pulikkotil S J, Suresh A, Veettil S K, Bhatia S, Setzer F C. Efficacy of local anaesthetic solutions on the success of inferior alveolar nerve block in patients with irreversible pulpitis: a systematic review and network meta-analysis of randomized clinical trials. Int Endod J 2019; 52: 779-789.
St George G, Morgan A, Meechan J et al. Injectable local anaesthetic agents for dental anaesthesia. Cochrane Database Syst Rev 2018; DOI: 10.1002/14651858.CD006487.pub2.
Haas D A, Lennon D. A 21 year retrospective study of reports of paresthesia following local anesthetic administration. J Can Dent Assoc 1995; 61: 319-320, 323-326, 329-330.
Garisto G A, Gaffen A S, Lawrence H P, Tenenbaum H C, Haas D A. Occurrence of paresthesia after dental local anesthetic administration in the United States. J Am Dent Assoc 2010; 141: 836-844.
Tabrizi R, Mazidi A, Sharifzadeh H, Khanzadeh H, Azadi A. Occurrence of neurosensory disturbance after the use of articaine and lidocaine in the inferior alveolar nerve block: a double-blind randomised clinical trial. Br J Oral Maxillofac Surg 2024; 62: 637-641.
Yang F, Gao Y, Zhang L et al. Local anaesthesia for surgical extraction of mandibular third molars: a systematic review and network meta-analysis. Clin Oral Investig 2020; 24: 3781-3800.
Shahi S, Rahimi S, Yavari H R, Ghasemi N, Ahmadi F. Success Rate of 3 Injection Methods with Articaine for Mandibular First Molars with Symptomatic Irreversible Pulpitis: A CONSORT Randomized Double-blind Clinical Trial. J Endod 2018; 44: 1462-1466.
Kumar M, Singla R, Gill G S, Kalra T, Jain N. Evaluating Combined Effect of Oral Premedication with Ibuprofen and Dexamethasone on Success of Inferior Alveolar Nerve Block in Mandibular Molars with Symptomatic Irreversible Pulpitis: A Prospective, Double-blind, Randomized Clinical Trial. J Endod 2021; 47: 705-710.
Shirvani A, Shamszadeh S, Eghbal M J, Marvasti L A, Asgary S. Effect of preoperative oral analgesics on pulpal anesthesia in patients with irreversible pulpitis-a systematic review and meta-analysis. Clin Oral Investig 2017; 21: 43-52.
de Geus J L, Wambier L M, Boing T F, Loguercio A D, Reis A. Effect of ibuprofen on the efficacy of inferior alveolar nerve block in patients with irreversible pulpitis: A meta-analysis. Aust Endod J 2019; 45: 246-258.
Prasanna N, Subbarao C V, Gutmann J L. The efficacy of pre-operative oral medication of lornoxicam and diclofenac potassium on the success of inferior alveolar nerve block in patients with irreversible pulpitis: a double-blind, randomised controlled clinical trial. Int Endod J 2011; 44: 330-336.
Taha N A, Abdelkhader S Z. Outcome of full pulpotomy using Biodentine in adult patients with symptoms indicative of irreversible pulpitis. Int Endod J 2018; 51: 819-828.
Eren B, Onay E O, Ungor M. Assessment of alternative emergency treatments for symptomatic irreversible pulpitis: a randomized clinical trial. Int Endod J 2018; DOI: 10.1111/iej.12851.
Gemmell A, Stone S, Edwards D. Investigating acute management of irreversible pulpitis: a survey of general dental practitioners in North East England. Br Dent J 2020; 228: 521-526.
Edwards D, Bailey O, Stone S J, Duncan H. How is carious pulp exposure and symptomatic irreversible pulpitis managed in UK primary dental care? Int Endod J 2021; 54: 2256-2275.
Edwards D, Rasaiah S, Kirkevang L L et al. The use of medicaments in the management of symptomatic irreversible pulpitis: A community-based cohort study. Int Endod J 2024; 57: 416-430.
UK Government. Dental antimicrobial stewardship: toolkit. 2023. Available at https://www.gov.uk/guidance/dental-antimicrobial-stewardship-toolkit (accessed March 2025).
Nixdorf D R, Law A S, Lindquist K et al. Frequency, impact, and predictors of persistent pain after root canal treatment: a national dental PBRN study. Pain 2016; 157: 159-165.
Sorribes De Ramón L A, Ferrández MartÃnez A F, GarcÃa Carricondo A R, EspÃn Gálvez F, Alarcón RodrÃguez R. Effect of virtual reality and music therapy on anxiety and perioperative pain in surgical extraction of impacted third molars. J Am Dent Assoc 2023; 154: 206-214.
Smith E A, Marshall J G, Selph S S, Barker D R, Sedgley C M. Nonsteroidal Anti-inflammatory Drugs for Managing Postoperative Endodontic Pain in Patients Who Present with Preoperative Pain: A Systematic Review and Meta-analysis. J Endod 2017; 43: 7-15.
Miranda H F, Puig M M, Prieto J C, Pinardi G. Synergism between paracetamol and nonsteroidal anti-inflammatory drugs in experimental acute pain. Pain 2006; 121: 22-28.
Khan A A, Diogenes A. Pharmacological Management of Acute Endodontic Pain. Drugs 2021; 81: 1627-1643.
Catherine B, Rood J P. The application of clinical audit to improve pain control following third molar surgery. Dent Update 2013; DOI: 10.12968/denu.2013.40.8.659.
Elkhadem A, Ezzat K, Ramadan M et al. The effect of preoperative oral administration of prednisolone on postoperative pain in patients with symptomatic irreversible pulpitis: a single-centre randomized controlled trial. Int Endod J 2018; DOI: 10.1111/iej.12795.
Duncan H F, Galler K M, Tomson P L et al. European Society of Endodontology position statement: Management of deep caries and the exposed pulp. Int Endod J 2019; 52: 923-934.
Rossi-Fedele G, Rödig T. Effectiveness of root canal irrigation and dressing for the treatment of apical periodontitis: A systematic review and meta-analysis of clinical trials. Int Endod J 2023; DOI: 10.1111/iej.13777.
Siqueira Jr J F. Microbial causes of endodontic flare-ups. Int Endod J 2003; 36: 453-463.
Siqueira Jr J F, Rôças I N. Present status and future directions: Microbiology of endodontic infections. Int Endod J 2022; DOI: 10.1111/iej.13677.
Pratt I, Aminoshariae A, Montagnese T A, Williams K A, Khalighinejad N, Mickel A. Eight-Year Retrospective Study of the Critical Time Lapse between Root Canal Completion and Crown Placement: Its Influence on the Survival of Endodontically Treated Teeth. J Endod 2016; 42: 1598-1603.
Casati A, Putzu M. Bupivacaine, levobupivacaine and ropivacaine: are they clinically different? Best Pract Res Clin Anaesthesiol 2005; 19: 247-268.
Daline I H, Slade G D, Fouad A F, Nixdorf D R, Tchivileva I E. Prevalence of painful temporomandibular disorders in endodontic patients with tooth pain. J Oral Rehabil 2023; 50: 537-547.
Wright E F. Referred craniofacial pain patterns in patients with temporomandibular disorder. J Am Dent Assoc 2000; 131: 1307-1315.
Nixdorf D R, Law A S, John M T, Sobieh R M, Kohli R, Nguyen R H. Differential diagnoses for persistent pain after root canal treatment: a study in the National Dental Practice-based Research Network. J Endod 2015; 41: 457-463.
Beecroft E, Palmer J, Penlington C et al. Management of painful Temporomandibular disorder in adults NHS England Getting It Right First Time (GIRFT) and Royal College of Surgeons of England's Faculty of Dental Surgery. 2024. Available at https://www.rcseng.ac.uk/dental-faculties/fds/publications-guidelines/clinical-guidelines/ (accessed March 2025).
Allison J R, Offen E, Cowley T et al. How dental teams can help patients with temporomandibular disorders receive general dental care: An International Delphi process. J Oral Rehabil 2023; 50: 482-487.
Durham J, Stone S J, Robinson L J, Ohrbach R, Nixdorf D R. Development and preliminary evaluation of a new screening instrument for atypical odontalgia and persistent dentoalveolar pain disorder. Int Endod J 2019; 52: 279-287.
Neal T W, Zuniga J R. Post-traumatic Trigeminal Neuropathic Pain: Factors Affecting Surgical Treatment Outcomes. Front Oral Health 2022; 3: 904785.
Sanner F, Sonntag D, Hambrock N, Zehnder M. Patients with persistent idiopathic dentoalveolar pain in dental practice. Int Endod J 2022; 55: 231-239.
Sjögren J, Kvist T, List T, Eliasson A, Pigg M. Characteristics and impact of pain from root-filled teeth. A practice-based cross-sectional study comparing painful teeth with and without signs of inflammatory dental disease. J Oral Facial Pain Headache 2024; 38: 64-76.
List T, Leijon G, Svensson P. Somatosensory abnormalities in atypical odontalgia: A case-control study. Pain 2008; 139: 333-341.
Porporatti A L, Costa Y M, Stuginski-Barbosa J, Bonjardim L R, Duarte M A, Conti P C. Diagnostic Accuracy of Quantitative Sensory Testing to Discriminate Inflammatory Toothache and Intraoral Neuropathic Pain. J Endod 2015; 41: 1606-1613.
Baad-Hansen L, Pigg M, Ivanovic S E et al. Intraoral somatosensory abnormalities in patients with atypical odontalgia—a controlled multicenter quantitative sensory testing study. Pain 2013; 154: 1287-1294.
ICOP. International Classification of Orofacial Pain, 1st edition (ICOP). Cephalalgia 2020; 40: 129-221.
Pigg M, Baad-Hansen L, Svensson P, Drangsholt M, List T. Reliability of intraoral quantitative sensory testing (QST). Pain 2010; 148: 220-226.
Slade G D, Bair E, Greenspan J D et al. Signs and symptoms of first-onset TMD and sociodemographic predictors of its development: the OPPERA prospective cohort study. J Pain 2013; DOI: 10.1016/j.jpain.2013.07.014.
Bartley E J, Fillingim R B. Sex differences in pain: a brief review of clinical and experimental findings. Br J Anaesth 2013; 111: 52-58.
Mathé A A, Agren H, Lindström L, Theodorsson E. Increased concentration of calcitonin gene-related peptide in cerebrospinal fluid of depressed patients. A possible trait marker of major depressive disorder. Neurosci Lett 1994; 182: 138-142.
Won E, Kang J, Choi S et al. The association between substance P and white matter integrity in medication-naive patients with major depressive disorder. Sci Rep 2017; 7: 9707.
Kisely S, Sawyer E, Siskind D, Lalloo R. The oral health of people with anxiety and depressive disorders - a systematic review and meta-analysis. J Affect Disord 2016; 200: 119-132.
Yang S E, Park Y G, Han K, Min J A, Kim S Y. Dental pain related to quality of life and mental health in South Korean adults. Psychol Health Med 2016; 21: 981-992.
Karamat A, Smith J G, Melek L N F, Renton T. Psychologic Impact of Chronic Orofacial Pain: A Critical Review. J Oral Facial Pain Headache 2022; 36: 103-140.
Schiffman E, Ohrbach R, Truelove E et al. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Group†. J Oral Facial Pain Headache 2014; 28: 6-27.
Baad-Hansen L, Benoliel R. Neuropathic orofacial pain: Facts and fiction. Cephalalgia 2017; 37: 670-679.
Benoliel R, Birenboim R, Regev E, Eliav E. Neurosensory changes in the infraorbital nerve following zygomatic fractures. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 99: 657-665.
Ram S, Teruel A, Kumar S K, Clark G. Clinical characteristics and diagnosis of atypical odontalgia: implications for dentists. J Am Dent Assoc 2009; 140: 223-228.
Coulter J, Nixdorf J. A review of persistent idiopathic dentoalveolar pain (formerly PDAP/Atypical odontalgia). Oral Surgery 2020; DOI: 10.1111/ors.12472.
Author information
Authors and Affiliations
Contributions
DE, EB: conceptualisation, project administration, visualisation, writing - original draft publication, writing - review and editing. JRA, JC, JD: conceptualisation, visualisation, writing - original draft publication, writing - review and editing.
Corresponding author
Ethics declarations
The authors declare no conflicts of interest.
Rights and permissions
Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0.© The Author(s) 2025.
About this article
Cite this article
Edwards, D., Allison, J., Coulter, J. et al. Symptomatic irreversible pulpitis and other orofacial pain: overcoming challenges in diagnosis and management. Br Dent J 238, 517–526 (2025). https://doi.org/10.1038/s41415-025-8441-9
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41415-025-8441-9
This article is cited by
-
Changes in galectin-1 expression in pulp tissue and CD68 + macrophages in irreversible pulpitis and healthy pulp
Journal of Molecular Histology (2025)